Clinical Use of PPARγ Ligands in Cancer
Joint Authors
Hatton, Jennifer L.
Yee, Lisa D.
Source
Issue
Vol. 2008, Issue 2008 (31 Dec. 2008), pp.1-13, 13 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2008-12-18
Country of Publication
Egypt
No. of Pages
13
Main Subjects
Natural & Life Sciences (Multidisciplinary)
Biology
Abstract EN
The role of PPARγ in adipocyte differentiation has fueled intense interest in the function of this steroid nuclear receptor for regulation of malignant cell growth and differentiation.
Given the antiproliferative and differentiating effects of PPARγ ligands on liposarcoma cells, investigation of PPARγ expression and ligand activation in other solid tumors such as breast, colon, and prostate cancers ensued.
The anticancer effects of PPARγ ligands in cell culture and rodent models of a multitude of tumor types suggest broad applicability of these agents to cancer therapy.
This review focuses on the clinical use of PPARγ ligands, specifically the thiazolidinediones, for the treatment and prevention of cancer.
American Psychological Association (APA)
Hatton, Jennifer L.& Yee, Lisa D.. 2008. Clinical Use of PPARγ Ligands in Cancer. PPAR Research،Vol. 2008, no. 2008, pp.1-13.
https://search.emarefa.net/detail/BIM-450564
Modern Language Association (MLA)
Hatton, Jennifer L.& Yee, Lisa D.. Clinical Use of PPARγ Ligands in Cancer. PPAR Research No. 2008 (2008), pp.1-13.
https://search.emarefa.net/detail/BIM-450564
American Medical Association (AMA)
Hatton, Jennifer L.& Yee, Lisa D.. Clinical Use of PPARγ Ligands in Cancer. PPAR Research. 2008. Vol. 2008, no. 2008, pp.1-13.
https://search.emarefa.net/detail/BIM-450564
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-450564